drTarget portfolio target-disease associations for Infectious diseases DrTarget’s AI-Powered Indication Expansion for Infectious Diseases

DrTarget’s AI-Driven Approach to Infectious Disease Research

DrTarget has identified 336 target proteins from PubChem screens associated with 515 infectious diseases, leveraging Open Targets and other public databases. By applying machine learning models and AI-driven analytics, we uncover new therapeutic targets and repurposing opportunities for antimicrobial and antiviral drug development.

Our AI-powered approach enables:

✔ Identification of novel drug targets for bacterial, viral, and parasitic infections
✔ Drug repurposing opportunities to accelerate treatment strategies
✔ Host-pathogen interaction analysis for precision medicine applications

By integrating AI-powered virtual screening and multi-source validation, DrTarget supports the discovery of new anti-infective therapies to combat emerging and drug-resistant pathogens.

Select genes or diseases. Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	HIV-1 infection	targetBased	67275	2509	0.417632019115235	224
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	infection	targetBased	394050	3624	0.587888525022768	255
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	infection	targetBased	325247	1021	0.295001179173854	57
HTS of Smad transcription factor inhibitors	SMAD3	infection	targetBased	88033	251	0.363448158025365	87
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	infection	targetBased	316642	617	0.523915285191001	83
uHTS identification of small molecule modulators of NR3A	GRIN3A	infection	targetBased	339772	8480	0.660276964107463	81
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	infection	pathwayBased	43989	342	0.332381905893642	798
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	infection	targetBased	343468	734	0.412883595696792	774
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	severe acute respiratory syndrome	targetBased	217959	2390	0.364012517510198	6
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	severe acute respiratory syndrome	pathwayBased	193265	3100	0.408633158137904	62
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	severe acute respiratory syndrome	pathwayBased	359244	3094	0.408633158137904	62
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	severe acute respiratory syndrome	targetBased	330392	1295	0.510857776805646	30
HTS of Smad transcription factor inhibitors	SMAD3	severe acute respiratory syndrome	targetBased	88033	251	0.511088225242917	8
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	severe acute respiratory syndrome	targetBased	314998	2199	0.507239609926207	6
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	severe acute respiratory syndrome	targetBased	343468	734	0.433588208983584	20
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	viral disease	targetBased	57013	201	0.533448005700228	76
HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	HP1-betaChromodomainInteractionsInhibitors	viral disease	targetBased	383363	2142	0.509151952880039	8
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	viral disease	targetBased	318291	483	0.425328012012717	29
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	viral disease	targetBased	343468	734	0.261521416976797	508
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	HIV infection	targetBased	290355	265	0.414922240062954	16
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	HIV infection	targetBased	86095	1442	0.575537830851285	26
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	HIV infection	targetBased	86095	1151	0.575537830851285	26
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	HIV infection	targetBased	143816	859	0.663611509897898	18
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	HIV infection	targetBased	46715	2829	0.408233132436577	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	HIV infection	targetBased	394050	3624	0.409048338790806	45
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	HIV infection	targetBased	335239	991	0.427570622736267	36
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	HIV infection	targetBased	335239	695	0.427570622736267	36
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	99314	335	0.385423106269835	39
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196176	782	0.385423106269835	39
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	99314	390	0.385423106269835	39
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196177	811	0.385423106269835	39
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196176	670	0.385423106269835	39
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196177	519	0.385423106269835	39
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	HIV infection	targetBased	369953	2353	0.648992922909193	91
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	HIV infection	targetBased	316642	617	0.305911386425869	6
qHTS for Inhibitors of Vif-A3G Interactions: qHTS	APOBEC3G_inhibitors	HIV infection	targetBased	402348	311	0.618941190389532	116
uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3G_inhibitors	HIV infection	targetBased	331753	931	0.618941190389532	116
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	malaria	targetBased	316642	617	0.509680221819924	11
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	malaria	targetBased	343468	734	0.642740677354967	196
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	urinary tract infection	targetBased	86095	1442	0.598304433739899	28
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	urinary tract infection	targetBased	86095	1151	0.598304433739899	28
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hepatitis C virus infection	targetBased	394050	3624	0.381339684466849	30
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	99314	335	0.544053842545307	19
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196176	782	0.544053842545307	19
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	99314	390	0.544053842545307	19
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196177	811	0.544053842545307	19
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196176	670	0.544053842545307	19
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196177	519	0.544053842545307	19
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	pneumonia	targetBased	217959	2390	0.322273166818187	10
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pneumonia	pathwayBased	362051	17187	0.292812792979543	77
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	pneumonia	targetBased	343468	734	0.374953231195365	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	chronic hepatitis C virus infection	targetBased	394050	3624	0.48907279326285	8
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	99314	335	0.556882803103682	6
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196176	782	0.556882803103682	6
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	99314	390	0.556882803103682	6
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196177	811	0.556882803103682	6
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196176	670	0.556882803103682	6
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196177	519	0.556882803103682	6
uHTS identification of small molecule modulators of NR3A	GRIN3A	chronic hepatitis C virus infection	targetBased	339772	8480	0.536969177145771	8
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	Creutzfeldt Jacob Disease	targetBased	369953	1596	0.794969944120682	206
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	chronic hepatitis B virus infection	targetBased	394050	3624	0.416323703141132	14
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	prion disease	targetBased	369953	1596	0.829860821013757	4242
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Herpes Zoster	targetBased	316642	617	0.286121727579184	6
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	influenza	targetBased	63696	220	0.406110621508939	6
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	influenza	targetBased	290726	2649	0.406110621508939	6
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	influenza	targetBased	217959	2390	0.286421877101544	10
qHTS for Inhibitors of TGF-b	TGFB1	influenza	pathwayBased	403345	4970	0.426507766239587	102
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	influenza	targetBased	394050	3624	0.284185473999202	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	bronchiolitis obliterans	targetBased	339297	1446	0.368678188787264	6
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	influenza	targetBased	316642	617	0.601285568397495	9
uHTS identification of small molecule modulators of NR3A	GRIN3A	influenza	targetBased	339772	8480	0.660725338872141	104
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	influenza	targetBased	343468	734	0.295920889253573	44
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	listeriosis	targetBased	193542	587	0.593396752228544	8
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	coronavirus infectious disease	targetBased	343468	734	0.419752638612533	14
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	septic shock	targetBased	335239	991	0.601285568397495	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	septic shock	targetBased	335239	695	0.601285568397495	9
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	septic shock	targetBased	324747	813	0.613407008594561	33
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	septic shock	targetBased	290355	265	0.577168330395272	6
uHTS identification of small molecule modulators of NR3A	GRIN3A	septic shock	targetBased	339772	8480	0.536969177145771	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	septic shock	targetBased	339297	1446	0.638939480030344	42
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	viral pneumonia	targetBased	343468	734	0.318572936377036	8
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	susceptibility to childhood ear infection measurement	targetBased	306502	3633	0.382327220816372	6
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	susceptibility to childhood ear infection measurement	targetBased	335180	1022	0.382327220816372	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	serum lipopolysaccharide activity	targetBased	339297	1446	0.407834936241567	17
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	pulmonary tuberculosis	targetBased	394050	3624	0.39163880691884	104
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Helicobacter pylori infectious disease	targetBased	394050	3624	0.298431454792675	15
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Recurrent infection of the gastrointestinal tract	targetBased	335239	991	0.595650699705387	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Recurrent infection of the gastrointestinal tract	targetBased	335239	695	0.595650699705387	9
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Sepsis	targetBased	217959	2390	0.294934461313262	71
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Sepsis	targetBased	394050	3624	0.551397408916636	46
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	Sepsis	targetBased	324747	813	0.406557917385719	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Sepsis	targetBased	339297	1446	0.6612711090907	66
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Sepsis	targetBased	316642	617	0.316719591125081	56
HCS assay for microtubule stabilizers	TUBB	fungal infectious disease	targetBased	195821	1625	0.507022442086813	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	nasopharyngeal carcinoma	pathwayBased	321427	201	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	54509	528	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	54513	338	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	125394	1890	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	124022	1156	0.737012287640562	68
HCS assay for microtubule stabilizers	TUBB	nasopharyngeal carcinoma	targetBased	195821	1625	0.458606950008097	98
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	tuberculosis	targetBased	394050	3624	0.446708744563635	223
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)	ASAP1_inhibitors	tuberculosis	targetBased	362577	680	0.413430315879523	24
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	respiratory tract infectious disorder	targetBased	75924	1804	0.251958915626748	8
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	respiratory tract infectious disorder	targetBased	316642	617	0.441745739262982	10
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	postherpetic neuralgia	targetBased	316642	617	0.443995984976086	15
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	COVID-19	targetBased	63696	220	0.290490012238163	42
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	COVID-19	targetBased	290726	2649	0.290490012238163	42
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	COVID-19	targetBased	217959	2390	0.455374500916603	189
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	COVID-19	targetBased	359207	1432	0.400618075800315	20
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	COVID-19	targetBased	363840	3086	0.52529188517202	104
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	COVID-19	targetBased	143816	859	0.436786846668777	8
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	COVID-19	targetBased	363803	2412	0.294971288860141	9
uHTS HTRF assay for identification of inhibitors of SUMOylation	UBE2I	COVID-19	targetBased	290915	1039	0.406922042600603	6
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	COVID-19	targetBased	394050	3624	0.661807962739989	108
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	COVID-19	targetBased	335239	991	0.324128571915494	14
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	COVID-19	targetBased	335239	695	0.324128571915494	14
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	COVID-19	pathwayBased	195980	5134	0.414354084594448	200
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	COVID-19	targetBased	195980	695	0.414354084594448	200
uHTS identification of SUMO1-mediated protein-protein interactions	SUMO1	COVID-19	targetBased	363840	1202	0.409751479216971	9
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	COVID-19	pathwayBased	362051	17187	0.332705533107256	2165
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	COVID-19	targetBased	306502	3633	0.406313476781855	6
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	COVID-19	targetBased	335180	1022	0.406313476781855	6
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	COVID-19	targetBased	330392	1295	0.443727828132228	719
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	COVID-19	targetBased	339297	1446	0.316501490861286	20
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	COVID-19	targetBased	305610	3794	0.52560928186248	6
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	COVID-19	targetBased	339674	2841	0.52662355822706	8
Thrombin 1536 HTS	F2_modulation	COVID-19	targetBased	217233	557	0.412497319279211	612
HCS assay for microtubule stabilizers	TUBB	COVID-19	targetBased	195821	1625	0.570269521289546	42
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	COVID-19	targetBased	316642	617	0.401058368093982	26
uHTS identification of small molecule modulators of NR3A	GRIN3A	COVID-19	targetBased	339772	8480	0.400520831766368	9
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	COVID-19	targetBased	343468	734	0.681978936473465	329
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	central nervous system infection	targetBased	369953	1596	0.320854290764917	2389
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	infectious disorder of the nervous system	targetBased	369953	1596	0.320854290764917	2389
qHTS assay for re-activators of p53 using a Luc reporter	TP53	post-infectious disorder	pathwayBased	321427	201	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	54509	528	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	54513	338	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	125394	1890	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	124022	1156	0.279352313554424	326

Some of these associations have also gone through clinical trials.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	COVID-19	DILTIAZEM	targetBased	3	Withdrawn	01/05/2020	https://clinicaltrials.gov/study/NCT04372082	0.7	LoF	protect	evidence showed chloroquine is not effective against COVID-19
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	OLSALAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC03	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	OLSALAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC03	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	OLSALAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC03	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	OLSALAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC03	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	OLSALAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC03	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	OLSALAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sepsis	MORPHINE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02135055	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sepsis	MORPHINE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02135055	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	MORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA52	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	MORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA52	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	HIV infection	CODEINE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	GoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	CODEINE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	GoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	CODEINE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	GoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	COVID-19	CHLORPROMAZINE	targetBased	3	Not yet recruiting	29/04/2020	https://clinicaltrials.gov/study/NCT04366739	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90e2d85-ed94-2c00-e053-2a95a90ad2a0	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90e2d85-ed94-2c00-e053-2a95a90ad2a0	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	septic shock	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90e2d85-ed94-2c00-e053-2a95a90ad2a0	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	septic shock	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Sepsis	METOCLOPRAMIDE	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00395161	0.35	LoF	protect	Terminated for futility on 11/30/09 based on the recommendation of the DSMB
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Sepsis	METOCLOPRAMIDE	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00395161	0.35	LoF	protect	Terminated for futility on 11/30/09 based on the recommendation of the DSMB
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Sepsis	METOCLOPRAMIDE	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00395161	0.35	LoF	protect	Terminated for futility on 11/30/09 based on the recommendation of the DSMB
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Sepsis	METOCLOPRAMIDE	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00395161	0.35	LoF	protect	Terminated for futility on 11/30/09 based on the recommendation of the DSMB
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Sepsis	METOCLOPRAMIDE	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00395161	0.35	LoF	protect	Terminated for futility on 11/30/09 based on the recommendation of the DSMB
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Sepsis	METOCLOPRAMIDE	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00395161	0.35	LoF	protect	Terminated for futility on 11/30/09 based on the recommendation of the DSMB
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	HIV infection	METOCLOPRAMIDE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	LoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	HIV infection	METOCLOPRAMIDE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	LoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	HIV infection	METOCLOPRAMIDE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	LoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	HIV infection	METOCLOPRAMIDE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	LoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	HIV infection	METOCLOPRAMIDE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	LoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	HIV infection	METOCLOPRAMIDE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	LoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	13/11/2017	https://clinicaltrials.gov/study/NCT03306121	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	PACLITAXEL	targetBased	3	Not yet recruiting	01/03/2021	https://clinicaltrials.gov/study/NCT04766359	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	PACLITAXEL	targetBased	3	Completed	20/10/2016	https://clinicaltrials.gov/study/NCT02940925	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	HIV-1 infection	PACLITAXEL	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01435018	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Not yet recruiting	01/06/2018	https://clinicaltrials.gov/study/NCT03503136	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01536223	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02621970	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Recruiting	04/12/2023	https://clinicaltrials.gov/study/NCT06118333	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/01/2011	https://clinicaltrials.gov/study/NCT01245959	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT02434614	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Recruiting	01/01/2015	https://clinicaltrials.gov/study/NCT02633176	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/11/2011	https://clinicaltrials.gov/study/NCT01479504	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Recruiting	01/08/2015	https://clinicaltrials.gov/study/NCT02512315	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Recruiting	31/01/2018	https://clinicaltrials.gov/study/NCT03919552	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT02012062	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02786641	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	nasopharyngeal carcinoma	DOCETAXEL	targetBased	3	Recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04437329	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Active, not recruiting	08/09/2020	https://clinicaltrials.gov/study/NCT04997551	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Withdrawn	15/12/2020	https://clinicaltrials.gov/study/NCT04603690	0.7	LoF	protect	No funding available
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Completed	19/08/2020	https://clinicaltrials.gov/study/NCT04416334	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	4	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT05246072	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Completed	21/04/2020	https://clinicaltrials.gov/study/NCT04324463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Terminated	21/01/2021	https://clinicaltrials.gov/study/NCT04516941	0.7	LoF	protect	Insufficient rate of patient accrual and newly available scientific evidence
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Completed	17/04/2020	https://clinicaltrials.gov/study/NCT04328480	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Terminated	30/04/2021	https://clinicaltrials.gov/study/NCT04539873	0.7	LoF	protect	non-inclusion of patients in the study effectively
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Completed	01/12/2020	https://clinicaltrials.gov/study/NCT04667780	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Completed	05/01/2021	https://clinicaltrials.gov/study/NCT04724629	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Terminated	23/03/2020	https://clinicaltrials.gov/study/NCT04322682	0.7	LoF	protect	Due to several considerations (logistical, human and budgetary), the study was stopped early.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Completed	30/04/2020	https://clinicaltrials.gov/study/NCT04350320	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	COVID-19	COLCHICINE	targetBased	3	Completed	30/10/2020	https://clinicaltrials.gov/study/NCT04472611	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	severe acute respiratory syndrome	COLCHICINE	targetBased	3	Terminated	21/01/2021	https://clinicaltrials.gov/study/NCT04516941	0.7	LoF	protect	Insufficient rate of patient accrual and newly available scientific evidence
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	severe acute respiratory syndrome	COLCHICINE	targetBased	3	Completed	21/04/2020	https://clinicaltrials.gov/study/NCT04324463	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	severe acute respiratory syndrome	COLCHICINE	targetBased	3	Recruiting	19/03/2020	https://clinicaltrials.gov/study/NCT04381936	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pneumococcal infection	ACETAMINOPHEN	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01392378	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	bacterial meningitis	ACETAMINOPHEN	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00619203	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	bacterial meningitis	ACETAMINOPHEN	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01540838	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	respiratory tract infectious disorder	ACETAMINOPHEN	targetBased	3	Withdrawn	01/02/2017	https://clinicaltrials.gov/study/NCT02678234	0.7		protect	The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	respiratory tract infectious disorder	ACETAMINOPHEN	targetBased	3	Withdrawn	01/02/2017	https://clinicaltrials.gov/study/NCT02730364	0.7		protect	The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	streptococcal infection	ACETAMINOPHEN	targetBased	3	Completed	02/07/2007	https://clinicaltrials.gov/study/NCT00496015	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	streptococcal infection	ACETAMINOPHEN	targetBased	4	Completed	12/11/2010	https://clinicaltrials.gov/study/NCT01235949	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	COVID-19	ACETAMINOPHEN	targetBased	3	Completed	19/08/2020	https://clinicaltrials.gov/study/NCT04416334	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	COVID-19	ACETAMINOPHEN	targetBased	3	Recruiting	02/06/2020	https://clinicaltrials.gov/study/NCT04536051	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	COVID-19	ACETAMINOPHEN	targetBased	3	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04673214	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Sepsis	ACETAMINOPHEN	targetBased	3	Suspended	01/08/2010	https://clinicaltrials.gov/study/NCT01182974	0.7		protect	Difficulty in patient enrollment
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	influenza	ACETAMINOPHEN	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT01389518	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	influenza	ACETAMINOPHEN	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01891084	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	influenza	ACETAMINOPHEN	targetBased	4	Not yet recruiting	10/02/2019	https://clinicaltrials.gov/study/NCT03754686	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	influenza	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b04b21b-ee68-4c59-91ad-57c3d84e2b09	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	influenza	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f1bb6e5-3de5-48b4-bf44-d4e881be5ab0	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	influenza	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=720366f1-f2d1-6dd6-7bf1-9fdd9378b073	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	HIV infection	ACETAMINOPHEN	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7		protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	malaria	ACETAMINOPHEN	targetBased	3	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT03056391	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	malaria	ACETAMINOPHEN	targetBased	4	Unknown status	01/05/2004	https://clinicaltrials.gov/study/NCT00137566	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	infection	ACETAMINOPHEN	targetBased	3	Completed	20/03/2017	https://clinicaltrials.gov/study/NCT02582307	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	infection	ACETAMINOPHEN	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00377403	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	infection	ACETAMINOPHEN	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00370318	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Plasmodium falciparum malaria	ACETAMINOPHEN	targetBased	4	Unknown status	01/05/2004	https://clinicaltrials.gov/study/NCT00137566	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Plasmodium falciparum malaria	ACETAMINOPHEN	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02974348	0.7		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00926614	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00926614	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00926614	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00926614	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00926614	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00926614	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV-Associated Lipodystrophy Syndrome	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV-Associated Lipodystrophy Syndrome	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV-Associated Lipodystrophy Syndrome	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV-Associated Lipodystrophy Syndrome	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV-Associated Lipodystrophy Syndrome	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV-Associated Lipodystrophy Syndrome	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV infection	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV infection	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV infection	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV infection	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV infection	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	HIV infection	PIOGLITAZONE	targetBased	3	Terminated	01/02/2003	https://clinicaltrials.gov/study/NCT00148850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01025765	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01025765	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01025765	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01025765	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01025765	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Unknown status	01/11/2009	https://clinicaltrials.gov/study/NCT01025765	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00189163	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00189163	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00189163	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00189163	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00189163	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00189163	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00545233	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00545233	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00545233	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00545233	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00545233	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	chronic hepatitis C virus infection	PIOGLITAZONE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00545233	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	abscess	FENTANYL	targetBased	3	Completed	01/08/2019	https://clinicaltrials.gov/study/NCT03872700	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	abscess	FENTANYL	targetBased	3	Completed	01/08/2019	https://clinicaltrials.gov/study/NCT03872700	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	abscess	FENTANYL	targetBased	4	Withdrawn	01/06/2011	https://clinicaltrials.gov/study/NCT01881997	1	GoF	protect	IRB modifications made study impractical.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	abscess	FENTANYL	targetBased	4	Withdrawn	01/06/2011	https://clinicaltrials.gov/study/NCT01881997	1	GoF	protect	IRB modifications made study impractical.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	COVID-19	FENTANYL	targetBased	3	Not yet recruiting	01/02/2022	https://clinicaltrials.gov/study/NCT05165992	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	COVID-19	FENTANYL	targetBased	3	Not yet recruiting	01/02/2022	https://clinicaltrials.gov/study/NCT05165992	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ear infection	FENTANYL	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00654329	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ear infection	FENTANYL	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00654329	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	FENTANYL	targetBased	4	Completed	25/01/2018	https://clinicaltrials.gov/study/NCT03251170	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	FENTANYL	targetBased	4	Completed	25/01/2018	https://clinicaltrials.gov/study/NCT03251170	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	ROSIGLITAZONE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00207402	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	ROSIGLITAZONE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00207402	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	ROSIGLITAZONE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00207402	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	ROSIGLITAZONE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00207402	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	ROSIGLITAZONE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00207402	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	hepatitis C virus infection	ROSIGLITAZONE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00207402	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	HIV infection	NALTREXONE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01625091	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	NALTREXONE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01625091	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	NALTREXONE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01625091	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	COVID-19	NEBIVOLOL	targetBased	3	Active, not recruiting	10/01/2021	https://clinicaltrials.gov/study/NCT04631536	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic hepatitis C virus infection	METHADONE	targetBased	4	Terminated	01/08/2005	https://clinicaltrials.gov/study/NCT00279565	1	GoF	protect	The trial was terminated because of deviations from the protocol.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic hepatitis C virus infection	METHADONE	targetBased	4	Terminated	01/08/2005	https://clinicaltrials.gov/study/NCT00279565	1	GoF	protect	The trial was terminated because of deviations from the protocol.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postherpetic neuralgia	METHADONE	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT01752699	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postherpetic neuralgia	METHADONE	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT01752699	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	METHADONE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01131273	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	METHADONE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01131273	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRADIOL	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01958073	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRADIOL	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01958073	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRADIOL	targetBased	4	Enrolling by invitation	31/01/2023	https://clinicaltrials.gov/study/NCT05551949	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRADIOL	targetBased	4	Enrolling by invitation	31/01/2023	https://clinicaltrials.gov/study/NCT05551949	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRADIOL	targetBased	4	Recruiting	12/01/2024	https://clinicaltrials.gov/study/NCT05723601	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRADIOL	targetBased	4	Recruiting	12/01/2024	https://clinicaltrials.gov/study/NCT05723601	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	HIV infection	ESTRADIOL	targetBased	4	Recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05663892	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	HIV infection	ESTRADIOL	targetBased	4	Recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05663892	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		COVID-19	AMANTADINE	targetBased	3	Recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT04894617	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		COVID-19	AMANTADINE	targetBased	3	Terminated	30/03/2021	https://clinicaltrials.gov/study/NCT04952519	0.35	LoF	protect	The annual analysis did not show the efficacy of the investigational medicinal product in this application, therefore the study was not continued.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		COVID-19	AMANTADINE	targetBased	3	Recruiting	15/03/2021	https://clinicaltrials.gov/study/NCT04854759	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944ab74b-2657-4821-9f2a-e695b5f24d97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a3e25d-80fa-479f-a419-d9487281deff	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2caed21-e9a3-228e-70a8-de30a1b368be	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be411327-5ac7-46df-b5e4-32a11b419b15	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5232b933-1df9-43b4-8ac2-61bfa4855e68	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c74c9424-278d-4a52-8866-db66f6c3ac67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=076740b2-9a76-45e9-9d56-87e9f3b96e97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5989098d-2855-4b5f-9a06-64a83656c078	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef565b0-00ac-428e-b00c-e0c905659ecd	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b8c51d-e066-49bf-8302-6ddfc2702ba6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99351f6a-82d7-4d3b-a214-e48260a63d05	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c446aed2-1add-4b09-9cc2-69ab95ae12d2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=070d3275-4b91-441f-a4e6-5a67b7d768a5	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63d9d4aa-5f92-45b0-98d0-d6ec38b727cb	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c40ecd11-0b6e-4f13-bfba-8f011c60ca16	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01417f60-dbf3-4041-bf3c-51e6c9216f06	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce3e1ae0-17f4-4fa3-9d9c-4239c54ae6ea	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062b646c-5ad9-4836-9e47-8678e1f2da7e	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0637f133-1f9d-48b3-b82f-a4e16f926cd6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=baec41e5-d898-4fff-8261-de39f23bcb1e	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b6e5b07-b3ba-4717-9ccd-029c0b08cc7f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fb81272-194b-476e-a5a9-ea5c1d31c69f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		chronic hepatitis C virus infection	AMANTADINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00221624	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		chronic hepatitis C virus infection	AMANTADINE	targetBased	3	Completed	01/02/2000	https://clinicaltrials.gov/study/NCT00146016	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		chronic hepatitis C virus infection	AMANTADINE	targetBased	4	Unknown status	01/07/2002	https://clinicaltrials.gov/study/NCT00127777	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		chronic hepatitis C virus infection	AMANTADINE	targetBased	3	Unknown status	01/11/2005	https://clinicaltrials.gov/study/NCT00299923	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		chronic hepatitis C virus infection	AMANTADINE	targetBased	3	Terminated	01/10/2000	https://clinicaltrials.gov/study/NCT00122629	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fb81272-194b-476e-a5a9-ea5c1d31c69f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c74c9424-278d-4a52-8866-db66f6c3ac67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=076740b2-9a76-45e9-9d56-87e9f3b96e97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=070d3275-4b91-441f-a4e6-5a67b7d768a5	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5232b933-1df9-43b4-8ac2-61bfa4855e68	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944ab74b-2657-4821-9f2a-e695b5f24d97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b6e5b07-b3ba-4717-9ccd-029c0b08cc7f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c446aed2-1add-4b09-9cc2-69ab95ae12d2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99351f6a-82d7-4d3b-a214-e48260a63d05	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b8c51d-e066-49bf-8302-6ddfc2702ba6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef565b0-00ac-428e-b00c-e0c905659ecd	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5989098d-2855-4b5f-9a06-64a83656c078	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be411327-5ac7-46df-b5e4-32a11b419b15	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c40ecd11-0b6e-4f13-bfba-8f011c60ca16	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2caed21-e9a3-228e-70a8-de30a1b368be	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63d9d4aa-5f92-45b0-98d0-d6ec38b727cb	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce3e1ae0-17f4-4fa3-9d9c-4239c54ae6ea	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0637f133-1f9d-48b3-b82f-a4e16f926cd6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062b646c-5ad9-4836-9e47-8678e1f2da7e	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a3e25d-80fa-479f-a419-d9487281deff	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01417f60-dbf3-4041-bf3c-51e6c9216f06	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=baec41e5-d898-4fff-8261-de39f23bcb1e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b7a4364-668d-4eb2-a20c-04adc35aabe4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59c1261b-0239-4b78-9349-b64cdce5ca5d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b5282a9-b149-4f0a-978e-5adbf48ec8aa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef18a92f-ba83-4bb0-808b-d09d736f6a81	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	croup	EPINEPHRINE	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT01664507	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bacteriemia	EPINEPHRINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT02150031	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	respiratory syncytial virus bronchiolitis	EPINEPHRINE	targetBased	4	Terminated	01/12/2000	https://clinicaltrials.gov/study/NCT00361452	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	HIV infection	ETHINYL ESTRADIOL	targetBased	4	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00042289	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	HIV infection	ETHINYL ESTRADIOL	targetBased	4	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00042289	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	HIV infection	ETHINYL ESTRADIOL	targetBased	4	Terminated	01/08/2015	https://clinicaltrials.gov/study/NCT02531321	1	GoF	protect	Difficulty recruiting
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	HIV infection	ETHINYL ESTRADIOL	targetBased	4	Terminated	01/08/2015	https://clinicaltrials.gov/study/NCT02531321	1	GoF	protect	Difficulty recruiting
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	transverse myelitis	DALFAMPRIDINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01446575	1	LoF	protect	This study was redesigned to be more statistically rigorous.
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	transverse myelitis	DALFAMPRIDINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01446575	1	LoF	protect	This study was redesigned to be more statistically rigorous.
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	transverse myelitis	DALFAMPRIDINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01446575	1	LoF	protect	This study was redesigned to be more statistically rigorous.
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	transverse myelitis	DALFAMPRIDINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01446575	1	LoF	protect	This study was redesigned to be more statistically rigorous.
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	transverse myelitis	DALFAMPRIDINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01446575	1	LoF	protect	This study was redesigned to be more statistically rigorous.
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	transverse myelitis	DALFAMPRIDINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01446575	1	LoF	protect	This study was redesigned to be more statistically rigorous.
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	transverse myelitis	DALFAMPRIDINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01446575	1	LoF	protect	This study was redesigned to be more statistically rigorous.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	MESALAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC02	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	MESALAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC02	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	MESALAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC02	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	MESALAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC02	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	MESALAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC02	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Recurrent infection of the gastrointestinal tract	MESALAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07EC02	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	respiratory syncytial virus bronchiolitis	ALBUTEROL	targetBased	4	Terminated	01/12/2000	https://clinicaltrials.gov/study/NCT00361452	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		septic shock	KETAMINE	targetBased	4	Completed	25/01/2018	https://clinicaltrials.gov/study/NCT03251170	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		septic shock	KETAMINE	targetBased	3	Completed	12/04/2017	https://clinicaltrials.gov/study/NCT03104140	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		septic shock	KETAMINE	targetBased	3	Unknown status	20/12/2018	https://clinicaltrials.gov/study/NCT03640468	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		septic shock	KETAMINE	targetBased	3	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT03844984	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	ESMOLOL	targetBased	3	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02609152	0.7	LoF	protect	logistical difficulties
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	LOPERAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	LOPERAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	LOPERAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA53	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	LOPERAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA53	1	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	HIV infection	LENALIDOMIDE	targetBased	4	Recruiting	20/11/2022	https://clinicaltrials.gov/study/NCT05598580	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	COVID-19	LENALIDOMIDE	targetBased	4	Not yet recruiting	27/10/2020	https://clinicaltrials.gov/study/NCT04361643	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Epstein-Barr virus infection	LENALIDOMIDE	targetBased	3	Recruiting	15/09/2019	https://clinicaltrials.gov/study/NCT04084626	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fungal infectious disease	VINBLASTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	DOBUTAMINE	targetBased	4	Unknown status	01/06/2007	https://clinicaltrials.gov/study/NCT00484133	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	COVID-19	IMATINIB	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	COVID-19	IMATINIB	targetBased	3	Active, not recruiting	02/06/2020	https://clinicaltrials.gov/study/NCT04394416	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	COVID-19	IMATINIB	targetBased	3	Active, not recruiting	18/03/2020	https://clinicaltrials.gov/study/NCT04330690	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	influenza	IMATINIB	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pneumonia	IMATINIB	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	postherpetic neuralgia	CAPSAICIN	targetBased	4	Completed	28/10/2010	https://clinicaltrials.gov/study/NCT01252160	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Herpes Zoster	CAPSAICIN	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00115310	0.7		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory tract infectious disorder	REMIFENTANIL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00611195	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory tract infectious disorder	REMIFENTANIL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00611195	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postherpetic neuralgia	REMIFENTANIL	targetBased	3	Unknown status	01/08/2010	https://clinicaltrials.gov/study/NCT01102101	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postherpetic neuralgia	REMIFENTANIL	targetBased	3	Unknown status	01/08/2010	https://clinicaltrials.gov/study/NCT01102101	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	REMIFENTANIL	targetBased	3	Recruiting	31/05/2023	https://clinicaltrials.gov/study/NCT05839366	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	REMIFENTANIL	targetBased	3	Recruiting	31/05/2023	https://clinicaltrials.gov/study/NCT05839366	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Sepsis	CHOLECALCIFEROL	targetBased	4	Completed	01/03/2022	https://clinicaltrials.gov/study/NCT05244018	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	tuberculosis	CHOLECALCIFEROL	targetBased	3	Unknown status	01/05/2008	https://clinicaltrials.gov/study/NCT00507000	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	tuberculosis	CHOLECALCIFEROL	targetBased	3	Completed	14/03/2017	https://clinicaltrials.gov/study/NCT02880982	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	tuberculosis	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00419068	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	tuberculosis	CHOLECALCIFEROL	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02276755	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	HIV infection	CHOLECALCIFEROL	targetBased	3	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02426840	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	HIV infection	CHOLECALCIFEROL	targetBased	3	Completed	15/06/2015	https://clinicaltrials.gov/study/NCT02305927	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	HIV infection	CHOLECALCIFEROL	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01798680	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	influenza	CHOLECALCIFEROL	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01182870	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	infection	CHOLECALCIFEROL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01395290	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	infection	CHOLECALCIFEROL	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02388516	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	infection	CHOLECALCIFEROL	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02617771	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Helicobacter pylori infectious disease	CHOLECALCIFEROL	targetBased	3	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT03142620	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hepatitis C virus infection	CHOLECALCIFEROL	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02053519	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pulmonary tuberculosis	CHOLECALCIFEROL	targetBased	3	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00366470	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	3	Completed	15/04/2020	https://clinicaltrials.gov/study/NCT04344041	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	4	Completed	01/08/2021	https://clinicaltrials.gov/study/NCT04952857	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	4	Completed	12/11/2020	https://clinicaltrials.gov/study/NCT04636086	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	4	Recruiting	04/04/2020	https://clinicaltrials.gov/study/NCT04552951	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	3	Completed	15/07/2020	https://clinicaltrials.gov/study/NCT04502667	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	3	Terminated	12/07/2021	https://clinicaltrials.gov/study/NCT04780061	0.7	GoF	protect	Public PCR testing stopped in Ontario
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	3	Active, not recruiting	19/03/2021	https://clinicaltrials.gov/study/NCT04385940	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	3	Completed	15/07/2020	https://clinicaltrials.gov/study/NCT04535791	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	CHOLECALCIFEROL	targetBased	3	Completed	22/04/2021	https://clinicaltrials.gov/study/NCT04641195	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pneumonia	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02936895	1	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	HIV-1 infection	VINCRISTINE	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01435018	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	COVID-19	ARGATROBAN	targetBased	4	Terminated	13/10/2020	https://clinicaltrials.gov/study/NCT04406389	1	LoF	protect	Low accrual
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	COVID-19	ISOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	COVID-19	ISOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	septic shock	ISOFLURANE	targetBased	4	Recruiting	15/12/2020	https://clinicaltrials.gov/study/NCT04710914	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	septic shock	ISOFLURANE	targetBased	4	Recruiting	15/12/2020	https://clinicaltrials.gov/study/NCT04710914	1		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchiolitis obliterans	SALMETEROL	targetBased	3	Terminated	21/05/2021	https://clinicaltrials.gov/study/NCT04655508	0.7	GoF	protect	insufficient enrollment.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	postpoliomyelitis syndrome	MODAFINIL	targetBased	3	Terminated	01/08/2003	https://clinicaltrials.gov/study/NCT00067496	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRIOL	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00900653	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTRIOL	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00900653	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	urinary tract infection	ESTRIOL	targetBased	4	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00900653	1		protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fungal infectious disease	VINBLASTINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	septic shock	VASOPRESSIN	targetBased	4	Withdrawn	03/01/2022	https://clinicaltrials.gov/study/NCT05193370	1	GoF	protect	Funding and protocol changes. Replaced with new pilot trial.
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	septic shock	VASOPRESSIN	targetBased	4	Withdrawn	01/11/2015	https://clinicaltrials.gov/study/NCT02454348	1	GoF	protect	PI left
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	septic shock	VASOPRESSIN	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01718613	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	septic shock	VASOPRESSIN	targetBased	4	Enrolling by invitation	01/02/2024	https://clinicaltrials.gov/study/NCT06217562	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	septic shock	VASOPRESSIN	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05886192	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Sepsis	VASOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1147beb-743e-4c62-8927-91192447f8b8	1	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	TOFACITINIB	targetBased	3	Completed	16/09/2020	https://clinicaltrials.gov/study/NCT04469114	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	4	Withdrawn	01/11/2015	https://clinicaltrials.gov/study/NCT02454348	1	GoF	protect	PI left
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT02519699	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02085291	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	3	Recruiting	11/10/2022	https://clinicaltrials.gov/study/NCT05207280	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	3	Not yet recruiting	10/03/2020	https://clinicaltrials.gov/study/NCT04295993	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01718613	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00604019	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05886192	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00763906	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	septic shock	NOREPINEPHRINE	targetBased	3	Suspended	01/04/2019	https://clinicaltrials.gov/study/NCT03302650	0.7	GoF	protect	The drug is not available
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	poliomyelitis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=788b6c64-1b6d-0058-e053-2a91aa0aa99c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	serum lipopolysaccharide activity	NOREPINEPHRINE	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02675868	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb5e8d16-303f-49fc-8424-d57ce41b588d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	3	Completed	09/05/2016	https://clinicaltrials.gov/study/NCT02473263	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2b5320e-e6a6-4a43-8f3c-9c21195ceb4a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e0570e7-d28f-4936-cba8-81ee0c4c3547	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4	Recruiting	01/08/2023	https://clinicaltrials.gov/study/NCT05836272	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d3531fb-82a4-41ab-8c36-eb0aace61f5c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27fb6e0-8f7a-11db-9739-0050c2490048	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=521b3175-d997-494f-9722-74246fe4f55d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8896b6-b8ac-4d04-9d5f-60c21404e159	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c9dc6eb-e53a-4cc0-92c3-7a53d268cf93	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4	Unknown status	01/06/2007	https://clinicaltrials.gov/study/NCT00484133	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4de72a8-2a75-4984-ce90-e4870226dc12	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	3	Recruiting	11/10/2022	https://clinicaltrials.gov/study/NCT05179499	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3352c7d0-e621-46ed-9a54-e4a9583cde10	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		postherpetic neuralgia	ESKETAMINE	targetBased	4	Recruiting	25/11/2020	https://clinicaltrials.gov/study/NCT04664530	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		septic shock	ESKETAMINE	targetBased	3	Recruiting	31/05/2023	https://clinicaltrials.gov/study/NCT05839366	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	Lyme disease	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01207739	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	infection	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/04/2020	https://clinicaltrials.gov/study/NCT04336748	0.7	LoF	protect	Not feasible
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	infection	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	08/02/2021	https://clinicaltrials.gov/study/NCT05026801	0.7	LoF	protect	Inadequate support to carry out study
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	infection	HYDROXYCHLOROQUINE	targetBased	3	Completed	02/04/2020	https://clinicaltrials.gov/study/NCT04332991	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pneumocystosis	HYDROXYCHLOROQUINE	targetBased	3	Completed	06/02/2020	https://clinicaltrials.gov/study/NCT04261517	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	30/04/2020	https://clinicaltrials.gov/study/NCT04374942	0.35	LoF	protect	Due to unproven issues associated with hydroxychloroquine use and safety, further complicated by media and political misinformation which in effect rendered all global studies on HCQ to stop enrolling participants.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	02/04/2020	https://clinicaltrials.gov/study/NCT04332991	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Active, not recruiting	25/03/2020	https://clinicaltrials.gov/study/NCT04316377	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	06/04/2020	https://clinicaltrials.gov/study/NCT04328467	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	23/06/2020	https://clinicaltrials.gov/study/NCT04447534	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	06/02/2020	https://clinicaltrials.gov/study/NCT04261517	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Terminated	06/04/2020	https://clinicaltrials.gov/study/NCT04341493	0.5	LoF	protect	Concerns about safety of Hydroxychloroquine
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	22/03/2021	https://clinicaltrials.gov/study/NCT04858633	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Not yet recruiting	20/04/2020	https://clinicaltrials.gov/study/NCT04359615	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Completed	27/05/2020	https://clinicaltrials.gov/study/NCT04652648	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	30/04/2020	https://clinicaltrials.gov/study/NCT04361461	0.7	LoF	protect	This study was canceled before enrollment due to a decision by the Sponsor
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	11/04/2020	https://clinicaltrials.gov/study/NCT04355052	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	28/04/2020	https://clinicaltrials.gov/study/NCT04349228	0.7	LoF	protect	- Interest in the use of HCQ is controversial.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	02/04/2020	https://clinicaltrials.gov/study/NCT04334382	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	25/04/2020	https://clinicaltrials.gov/study/NCT04359953	0.7	LoF	protect	difficulty in recruiting
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Active, not recruiting	08/05/2020	https://clinicaltrials.gov/study/NCT04411433	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	04/04/2020	https://clinicaltrials.gov/study/NCT04341727	0.7	LoF	protect	DSMB recommended study suspension slow accrual
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	14/05/2020	https://clinicaltrials.gov/study/NCT04372017	0.7	LoF	protect	Unlikelihood of benefit based on other studies.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	15/04/2020	https://clinicaltrials.gov/study/NCT04334928	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	16/04/2020	https://clinicaltrials.gov/study/NCT04420247	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/04/2020	https://clinicaltrials.gov/study/NCT04342156	0.7	LoF	protect	The number of patients with COVID-19 in Singapore was coming down for the community and the concerns about the potential side effects particularly when the baseline ECG and serum electrolytes was not proposed.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	01/04/2020	https://clinicaltrials.gov/study/NCT04352933	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Withdrawn	01/05/2020	https://clinicaltrials.gov/study/NCT04338906	1	LoF	protect	lack of public funding; planned control arm with Hydroxychloroquine treatment showed out as not being standard of care anymore as time evolved.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Withdrawn	05/05/2020	https://clinicaltrials.gov/study/NCT04351919	1	LoF	protect	- Interest in the use of HCQ is controversial.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/04/2020	https://clinicaltrials.gov/study/NCT04330144	0.7	LoF	protect	No Participants Enrolled
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Enrolling by invitation	15/04/2020	https://clinicaltrials.gov/study/NCT04350671	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	14/04/2020	https://clinicaltrials.gov/study/NCT04315896	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	27/04/2020	https://clinicaltrials.gov/study/NCT04363450	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/04/2020	https://clinicaltrials.gov/study/NCT04371406	0.7	LoF	protect	Regulatory approvals have not been obtained
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	03/04/2020	https://clinicaltrials.gov/study/NCT04522466	0.7	LoF	protect	Stop of the study by competent authority (ANSM)
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	01/04/2020	https://clinicaltrials.gov/study/NCT04325893	0.7	LoF	protect	decrease in number of eligible patients
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	22/03/2020	https://clinicaltrials.gov/study/NCT04315948	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	22/04/2020	https://clinicaltrials.gov/study/NCT04338698	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Not yet recruiting	20/04/2020	https://clinicaltrials.gov/study/NCT04359316	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	28/03/2020	https://clinicaltrials.gov/study/NCT04328272	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	25/03/2020	https://clinicaltrials.gov/study/NCT04421664	0.7	LoF	protect	Request of Health Canada after publication of https://doi.org/10.7326/M20-4207
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	05/10/2020	https://clinicaltrials.gov/study/NCT04715295	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	29/03/2020	https://clinicaltrials.gov/study/NCT04342221	0.7	LoF	protect	Reduced acceptance of IMP
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	04/05/2020	https://clinicaltrials.gov/study/NCT04391127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	26/03/2020	https://clinicaltrials.gov/study/NCT04345692	0.35	LoF	protect	RECOVERY Trial results - no efficacy
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	25/06/2020	https://clinicaltrials.gov/study/NCT04414241	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/04/2020	https://clinicaltrials.gov/study/NCT04365231	0.7	LoF	protect	no authorization obtained
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	13/05/2020	https://clinicaltrials.gov/study/NCT04446104	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	24/04/2020	https://clinicaltrials.gov/study/NCT04352946	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Not yet recruiting	01/04/2020	https://clinicaltrials.gov/study/NCT04363203	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	13/04/2020	https://clinicaltrials.gov/study/NCT04329611	0.7	LoF	protect	Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	13/04/2020	https://clinicaltrials.gov/study/NCT04344444	0.35	LoF	protect	Lack of efficacy data from other studies
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	07/05/2020	https://clinicaltrials.gov/study/NCT04365582	0.7	LoF	protect	The PI decided.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	16/11/2020	https://clinicaltrials.gov/study/NCT04981379	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	01/05/2020	https://clinicaltrials.gov/study/NCT04347512	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	14/04/2020	https://clinicaltrials.gov/study/NCT04318015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Enrolling by invitation	15/04/2020	https://clinicaltrials.gov/study/NCT04350684	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Completed	28/04/2020	https://clinicaltrials.gov/study/NCT04370782	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Suspended	30/03/2020	https://clinicaltrials.gov/study/NCT04334967	1	LoF	protect	suspected unfavorable risk/benefit assessment
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/04/2020	https://clinicaltrials.gov/study/NCT04336748	0.7	LoF	protect	Not feasible
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Completed	12/05/2020	https://clinicaltrials.gov/study/NCT04466540	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	17/03/2020	https://clinicaltrials.gov/study/NCT04308668	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/05/2020	https://clinicaltrials.gov/study/NCT04358081	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/05/2020	https://clinicaltrials.gov/study/NCT04371523	0.35	LoF	protect	Study was not initiated due to evidence becoming available that did not support the use of hydroxychloroquine in this population, with potential risk of added harm
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/12/2020	https://clinicaltrials.gov/study/NCT04364815	0.7	LoF	protect	Investigators opted to change the design of the study.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	14/04/2020	https://clinicaltrials.gov/study/NCT04362332	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/05/2020	https://clinicaltrials.gov/study/NCT04360759	0.7	LoF	protect	Equipoise for hydroxychloquine was lost
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	17/04/2020	https://clinicaltrials.gov/study/NCT04344379	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	13/05/2020	https://clinicaltrials.gov/study/NCT04339816	0.35	LoF	protect	Steering Committee decision in accordance with stopping rule 1: Emergence of new data
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Terminated	15/04/2020	https://clinicaltrials.gov/study/NCT04351191	1	LoF	protect	Poor accrual
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	07/04/2020	https://clinicaltrials.gov/study/NCT04341441	0.35	LoF	protect	Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	22/04/2020	https://clinicaltrials.gov/study/NCT04334148	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Completed	06/12/2020	https://clinicaltrials.gov/study/NCT04746365	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	01/05/2020	https://clinicaltrials.gov/study/NCT04372082	0.7	LoF	protect	evidence showed chloroquine is not effective against COVID-19
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	10/04/2020	https://clinicaltrials.gov/study/NCT04355026	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	4	Terminated	14/04/2020	https://clinicaltrials.gov/study/NCT04346667	1	LoF	protect	Poor accrual.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Completed	03/04/2020	https://clinicaltrials.gov/study/NCT04331834	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	30/03/2020	https://clinicaltrials.gov/study/NCT04346329	0.7	LoF	protect	The study did not get financed. Never got started.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	17/04/2020	https://clinicaltrials.gov/study/NCT04347980	0.35	LoF	protect	ANSM RECOMMANDATION
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE	targetBased	3	Terminated	14/04/2020	https://clinicaltrials.gov/study/NCT04328285	0.7	LoF	protect	French authority's decision
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pneumonia	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pneumonia	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	01/05/2020	https://clinicaltrials.gov/study/NCT04347512	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	severe acute respiratory syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	06/04/2020	https://clinicaltrials.gov/study/NCT04328467	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	severe acute respiratory syndrome	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	19/03/2020	https://clinicaltrials.gov/study/NCT04381936	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	severe acute respiratory syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	14/04/2020	https://clinicaltrials.gov/study/NCT04315896	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	severe acute respiratory syndrome	HYDROXYCHLOROQUINE	targetBased	3	Terminated	25/03/2020	https://clinicaltrials.gov/study/NCT04421664	0.7	LoF	protect	Request of Health Canada after publication of https://doi.org/10.7326/M20-4207
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	severe acute respiratory syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	02/04/2020	https://clinicaltrials.gov/study/NCT04332991	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	severe acute respiratory syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	14/04/2020	https://clinicaltrials.gov/study/NCT04318015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	severe acute respiratory syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	17/03/2020	https://clinicaltrials.gov/study/NCT04308668	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	malaria	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34496b43-05a2-45fb-a769-52b12e099341	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	malaria	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7804f5d2-41a6-4523-a277-6967e984e88e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	malaria	HYDROXYCHLOROQUINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=P01BA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	malaria	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b82bbda6-64f2-4426-b4ec-254eeea895ae	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	influenza	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronavirus infectious disease	HYDROXYCHLOROQUINE	targetBased	3	Completed	17/03/2020	https://clinicaltrials.gov/study/NCT04308668	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronavirus infectious disease	HYDROXYCHLOROQUINE	targetBased	3	Completed	28/03/2020	https://clinicaltrials.gov/study/NCT04321278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronavirus infectious disease	HYDROXYCHLOROQUINE	targetBased	3	Terminated	07/04/2020	https://clinicaltrials.gov/study/NCT04341441	0.35	LoF	protect	Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronavirus infectious disease	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/04/2020	https://clinicaltrials.gov/study/NCT04322123	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronavirus infectious disease	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	30/04/2020	https://clinicaltrials.gov/study/NCT04361461	0.7	LoF	protect	This study was canceled before enrollment due to a decision by the Sponsor
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	viral pneumonia	HYDROXYCHLOROQUINE	targetBased	3	Completed	28/03/2020	https://clinicaltrials.gov/study/NCT04321278	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Sepsis	ERGOCALCIFEROL	targetBased	4	Completed	01/03/2022	https://clinicaltrials.gov/study/NCT05244018	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	tuberculosis	ERGOCALCIFEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01722396	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic hepatitis C virus infection	ERGOCALCIFEROL	targetBased	3	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01997203	0.7	GoF	protect	complete patients samples required
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic hepatitis C virus infection	ERGOCALCIFEROL	targetBased	4	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02120274	1	GoF	protect	New Brazilian Guidelines for Viral Hepatitis C and Coinfetions. It does not include the treatment of chronic HCV Metavir < F3 and abandon the use of interferon.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic hepatitis B virus infection	ERGOCALCIFEROL	targetBased	4	Completed	01/12/2018	https://clinicaltrials.gov/study/NCT05753280	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pulmonary tuberculosis	ERGOCALCIFEROL	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00677339	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	4	Completed	30/10/2020	https://clinicaltrials.gov/study/NCT05037253	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	3	Terminated	08/02/2021	https://clinicaltrials.gov/study/NCT04483635	0.7	GoF	protect	A premature discontinuation was recommended by the Data Safety Monitoring Board and agreed upon by the principal investigator, because the significantly lower recruitment than planned, in the context of mass vaccination of the target population.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	4	Active, not recruiting	01/04/2020	https://clinicaltrials.gov/study/NCT05166005	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	3	Terminated	14/05/2020	https://clinicaltrials.gov/study/NCT04372017	0.7	GoF	protect	Unlikelihood of benefit based on other studies.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	3	Active, not recruiting	28/12/2020	https://clinicaltrials.gov/study/NCT04536298	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	4	Completed	11/08/2020	https://clinicaltrials.gov/study/NCT04411446	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	3	Completed	09/11/2020	https://clinicaltrials.gov/study/NCT04621058	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	COVID-19	ERGOCALCIFEROL	targetBased	3	Completed	22/04/2021	https://clinicaltrials.gov/study/NCT04641195	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic hepatitis C virus infection	BUPRENORPHINE	targetBased	4	Terminated	01/08/2005	https://clinicaltrials.gov/study/NCT00279565	1	GoF	protect	The trial was terminated because of deviations from the protocol.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic hepatitis C virus infection	BUPRENORPHINE	targetBased	4	Terminated	01/08/2005	https://clinicaltrials.gov/study/NCT00279565	1	GoF	protect	The trial was terminated because of deviations from the protocol.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	chronic hepatitis C virus infection	BUPRENORPHINE	targetBased	4	Terminated	01/08/2005	https://clinicaltrials.gov/study/NCT00279565	1	GoF	protect	The trial was terminated because of deviations from the protocol.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	HIV infection	BUPRENORPHINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01131273	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	BUPRENORPHINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01131273	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	BUPRENORPHINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01131273	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		COVID-19	AMANTADINE HYDROCHLORIDE	targetBased	3	Recruiting	15/03/2021	https://clinicaltrials.gov/study/NCT04854759	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=baec41e5-d898-4fff-8261-de39f23bcb1e	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944ab74b-2657-4821-9f2a-e695b5f24d97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5232b933-1df9-43b4-8ac2-61bfa4855e68	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63d9d4aa-5f92-45b0-98d0-d6ec38b727cb	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c40ecd11-0b6e-4f13-bfba-8f011c60ca16	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0637f133-1f9d-48b3-b82f-a4e16f926cd6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a3e25d-80fa-479f-a419-d9487281deff	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b8c51d-e066-49bf-8302-6ddfc2702ba6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=070d3275-4b91-441f-a4e6-5a67b7d768a5	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=076740b2-9a76-45e9-9d56-87e9f3b96e97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce3e1ae0-17f4-4fa3-9d9c-4239c54ae6ea	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c446aed2-1add-4b09-9cc2-69ab95ae12d2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99351f6a-82d7-4d3b-a214-e48260a63d05	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2caed21-e9a3-228e-70a8-de30a1b368be	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be411327-5ac7-46df-b5e4-32a11b419b15	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fb81272-194b-476e-a5a9-ea5c1d31c69f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b6e5b07-b3ba-4717-9ccd-029c0b08cc7f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01417f60-dbf3-4041-bf3c-51e6c9216f06	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef565b0-00ac-428e-b00c-e0c905659ecd	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c74c9424-278d-4a52-8866-db66f6c3ac67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062b646c-5ad9-4836-9e47-8678e1f2da7e	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		influenza	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5989098d-2855-4b5f-9a06-64a83656c078	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be411327-5ac7-46df-b5e4-32a11b419b15	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=070d3275-4b91-441f-a4e6-5a67b7d768a5	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c74c9424-278d-4a52-8866-db66f6c3ac67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b8c51d-e066-49bf-8302-6ddfc2702ba6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5989098d-2855-4b5f-9a06-64a83656c078	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a3e25d-80fa-479f-a419-d9487281deff	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63d9d4aa-5f92-45b0-98d0-d6ec38b727cb	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=076740b2-9a76-45e9-9d56-87e9f3b96e97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=baec41e5-d898-4fff-8261-de39f23bcb1e	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0637f133-1f9d-48b3-b82f-a4e16f926cd6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef565b0-00ac-428e-b00c-e0c905659ecd	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b6e5b07-b3ba-4717-9ccd-029c0b08cc7f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99351f6a-82d7-4d3b-a214-e48260a63d05	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944ab74b-2657-4821-9f2a-e695b5f24d97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5232b933-1df9-43b4-8ac2-61bfa4855e68	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce3e1ae0-17f4-4fa3-9d9c-4239c54ae6ea	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fb81272-194b-476e-a5a9-ea5c1d31c69f	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062b646c-5ad9-4836-9e47-8678e1f2da7e	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c40ecd11-0b6e-4f13-bfba-8f011c60ca16	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2caed21-e9a3-228e-70a8-de30a1b368be	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01417f60-dbf3-4041-bf3c-51e6c9216f06	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c446aed2-1add-4b09-9cc2-69ab95ae12d2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		infection	AMANTADINE HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Completed	13/05/2020	https://clinicaltrials.gov/study/NCT04446104	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Active, not recruiting	25/03/2020	https://clinicaltrials.gov/study/NCT04316377	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Terminated	29/03/2020	https://clinicaltrials.gov/study/NCT04342221	0.7	LoF	protect	Reduced acceptance of IMP
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Terminated	14/04/2020	https://clinicaltrials.gov/study/NCT04346667	1	LoF	protect	Poor accrual.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Withdrawn	30/04/2020	https://clinicaltrials.gov/study/NCT04361461	0.7	LoF	protect	This study was canceled before enrollment due to a decision by the Sponsor
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Withdrawn	01/04/2020	https://clinicaltrials.gov/study/NCT04342156	0.7	LoF	protect	The number of patients with COVID-19 in Singapore was coming down for the community and the concerns about the potential side effects particularly when the baseline ECG and serum electrolytes was not proposed.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Terminated	15/04/2020	https://clinicaltrials.gov/study/NCT04351191	1	LoF	protect	Poor accrual
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Terminated	04/04/2020	https://clinicaltrials.gov/study/NCT04341727	0.7	LoF	protect	DSMB recommended study suspension slow accrual
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	malaria	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34496b43-05a2-45fb-a769-52b12e099341	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	malaria	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7804f5d2-41a6-4523-a277-6967e984e88e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	malaria	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b82bbda6-64f2-4426-b4ec-254eeea895ae	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	coronavirus infectious disease	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Withdrawn	30/04/2020	https://clinicaltrials.gov/study/NCT04361461	0.7	LoF	protect	This study was canceled before enrollment due to a decision by the Sponsor
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90e2d85-ed94-2c00-e053-2a95a90ad2a0	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	septic shock	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90e2d85-ed94-2c00-e053-2a95a90ad2a0	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	septic shock	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90e2d85-ed94-2c00-e053-2a95a90ad2a0	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	septic shock	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	infection	SCOPOLAMINE	targetBased	3	Completed	20/03/2017	https://clinicaltrials.gov/study/NCT02582307	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	infection	SCOPOLAMINE	targetBased	3	Completed	20/03/2017	https://clinicaltrials.gov/study/NCT02582307	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	infection	SCOPOLAMINE	targetBased	3	Completed	20/03/2017	https://clinicaltrials.gov/study/NCT02582307	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	infection	SCOPOLAMINE	targetBased	3	Completed	20/03/2017	https://clinicaltrials.gov/study/NCT02582307	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	infection	SCOPOLAMINE	targetBased	3	Completed	20/03/2017	https://clinicaltrials.gov/study/NCT02582307	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchiolitis obliterans	SALMETEROL XINAFOATE	targetBased	3	Terminated	21/05/2021	https://clinicaltrials.gov/study/NCT04655508	0.7	GoF	protect	insufficient enrollment.
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	COVID-19	SEVOFLURANE	targetBased	4	Terminated	16/04/2020	https://clinicaltrials.gov/study/NCT04359862	1		protect	Low recruitment ratio
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	COVID-19	SEVOFLURANE	targetBased	3	Completed	23/04/2020	https://clinicaltrials.gov/study/NCT04355962	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	COVID-19	SEVOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	COVID-19	SEVOFLURANE	targetBased	4	Terminated	16/04/2020	https://clinicaltrials.gov/study/NCT04359862	1		protect	Low recruitment ratio
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	COVID-19	SEVOFLURANE	targetBased	3	Completed	23/04/2020	https://clinicaltrials.gov/study/NCT04355962	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	COVID-19	SEVOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	severe acute respiratory syndrome	SEVOFLURANE	targetBased	3	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04530188	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	severe acute respiratory syndrome	SEVOFLURANE	targetBased	3	Completed	23/04/2020	https://clinicaltrials.gov/study/NCT04355962	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	severe acute respiratory syndrome	SEVOFLURANE	targetBased	3	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04530188	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	severe acute respiratory syndrome	SEVOFLURANE	targetBased	3	Completed	23/04/2020	https://clinicaltrials.gov/study/NCT04355962	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	infection	SEVOFLURANE	targetBased	4	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT04619160	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	infection	SEVOFLURANE	targetBased	4	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT04619160	1		protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	HIV infection	LITHIUM CARBONATE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01348282	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	HIV infection	LITHIUM CARBONATE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01348282	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	HIV infection	CODEINE PHOSPHATE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	GoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	CODEINE PHOSPHATE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	GoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	HIV infection	CODEINE PHOSPHATE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00147355	0.7	GoF	protect	28 of 168 patients only were enrolled, numbers too low to be conclusive
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	hepatitis C virus infection	ARMODAFINIL	targetBased	4	Terminated	01/10/2011	https://clinicaltrials.gov/study/NCT01470651	1	LoF	protect	European Medicines Agency issued a drug/drug interaction: sofosbuvir/modafinil
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	DIFENOXIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	DIFENOXIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA04	1	GoF	protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	empyema	UROKINASE	targetBased	3	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02165891	0.7		protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	infection	UROKINASE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02036255	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01958073	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	urinary tract infection	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01958073	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	urinary tract infection	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01958073	1	GoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	COVID-19	CANAKINUMAB	pathwayBased	3	Completed	30/04/2020	https://clinicaltrials.gov/study/NCT04362813	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	pneumonia	CANAKINUMAB	pathwayBased	3	Completed	30/04/2020	https://clinicaltrials.gov/study/NCT04362813	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	poliomyelitis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=788b6c64-1b6d-0058-e053-2a91aa0aa99c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2b5320e-e6a6-4a43-8f3c-9c21195ceb4a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4	Recruiting	01/08/2023	https://clinicaltrials.gov/study/NCT05836272	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb5e8d16-303f-49fc-8424-d57ce41b588d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=521b3175-d997-494f-9722-74246fe4f55d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e0570e7-d28f-4936-cba8-81ee0c4c3547	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c9dc6eb-e53a-4cc0-92c3-7a53d268cf93	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8896b6-b8ac-4d04-9d5f-60c21404e159	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3352c7d0-e621-46ed-9a54-e4a9583cde10	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d3531fb-82a4-41ab-8c36-eb0aace61f5c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a27fb6e0-8f7a-11db-9739-0050c2490048	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Sepsis	NOREPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4de72a8-2a75-4984-ce90-e4870226dc12	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	infection	ALFACALCIDOL	targetBased	4	Unknown status	10/01/2017	https://clinicaltrials.gov/study/NCT03292744	1	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	RUXOLITINIB	targetBased	3	Completed	02/05/2020	https://clinicaltrials.gov/study/NCT04362137	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	RUXOLITINIB	targetBased	3	Terminated	24/05/2020	https://clinicaltrials.gov/study/NCT04377620	0.7	LoF	protect	Study terminated by sponsor
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	infection	DACTOLISIB	pathwayBased	3	Completed	15/04/2019	https://clinicaltrials.gov/study/NCT04668352	0.7	LoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	severe acute respiratory syndrome	LEVOSIMENDAN	targetBased	3	Recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT04020003	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	severe acute respiratory syndrome	LEVOSIMENDAN	targetBased	3	Recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT04020003	0.7	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Recruiting	21/12/2021	https://clinicaltrials.gov/study/NCT05074420	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Completed	02/12/2020	https://clinicaltrials.gov/study/NCT04640168	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Not yet recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT05056558	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Not yet recruiting	06/04/2021	https://clinicaltrials.gov/study/NCT04832880	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Completed	04/04/2020	https://clinicaltrials.gov/study/NCT04890626	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Withdrawn	10/07/2021	https://clinicaltrials.gov/study/NCT04970719	0.7	LoF	protect	adequate cases were not available
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Completed	12/06/2020	https://clinicaltrials.gov/study/NCT04421027	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Recruiting	10/09/2020	https://clinicaltrials.gov/study/NCT04693026	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	COVID-19	BARICITINIB	targetBased	3	Completed	08/05/2020	https://clinicaltrials.gov/study/NCT04401579	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	severe acute respiratory syndrome	BARICITINIB	targetBased	3	Recruiting	19/03/2020	https://clinicaltrials.gov/study/NCT04381936	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	severe acute respiratory syndrome	BARICITINIB	targetBased	3	Recruiting	10/09/2020	https://clinicaltrials.gov/study/NCT04693026	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	influenza	BARICITINIB	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	pneumonia	BARICITINIB	targetBased	3	Recruiting	11/04/2016	https://clinicaltrials.gov/study/NCT02735707	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Sepsis	BARICITINIB	targetBased	3	Not yet recruiting	01/04/2026	https://clinicaltrials.gov/study/NCT06381661	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	severe acute respiratory syndrome	DIMETHYL FUMARATE	targetBased	3	Recruiting	19/03/2020	https://clinicaltrials.gov/study/NCT04381936	0.7	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Recurrent infection of the gastrointestinal tract	CROFELEMER	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07XA06	1	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Recurrent infection of the gastrointestinal tract	CROFELEMER	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07XA06	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	Recurrent infection of the gastrointestinal tract	CROFELEMER	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07XA06	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	Recurrent infection of the gastrointestinal tract	CROFELEMER	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07XA06	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	septic shock	TERLIPRESSIN	targetBased	4	Unknown status	27/07/2018	https://clinicaltrials.gov/study/NCT03336814	1		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	septic shock	TERLIPRESSIN	targetBased	3	Recruiting	11/10/2022	https://clinicaltrials.gov/study/NCT05207280	0.7		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	ELUXADOLINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Recurrent infection of the gastrointestinal tract	ELUXADOLINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A07DA06	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	COVID-19	1018 ISS	targetBased	3	Terminated	12/11/2021	https://clinicaltrials.gov/study/NCT05012787	0.7	GoF	protect	The study was early terminated considering the inability to enroll the required study population.
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	HSP90AA1	Heat shock protein HSP 90-alpha	COVID-19	CD24FC	targetBased	3	Completed	24/04/2020	https://clinicaltrials.gov/study/NCT04317040	0.7	LoF	protect
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	HSP90AA1	Full-length cDNA 5-PRIME end of clone CS0DN005YI08 of Adult brain of Homo sapiens , Heat shock protein HSP 90-alpha, Heat shock protein HSP 90-alpha	COVID-19	CD24FC	targetBased	3	Completed	24/04/2020	https://clinicaltrials.gov/study/NCT04317040	0.7	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

drTarget portfolio target-disease associations for Infectious diseases

DrTarget’s AI-Driven Approach to Infectious Disease Research

Our AI-powered approach enables:

✔ Identification of novel drug targets for bacterial, viral, and parasitic infections✔ Drug repurposing opportunities to accelerate treatment strategies✔ Host-pathogen interaction analysis for precision medicine applications

By integrating AI-powered virtual screening and multi-source validation, DrTarget supports the discovery of new anti-infective therapies to combat emerging and drug-resistant pathogens.

Select genes or diseases. Check best scored target-disease associations in table:

Some of these associations have also gone through clinical trials.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

✔ Identification of novel drug targets for bacterial, viral, and parasitic infections
✔ Drug repurposing opportunities to accelerate treatment strategies
✔ Host-pathogen interaction analysis for precision medicine applications